Toxicity Inhibitors Protect Lipid Membranes from Disruption by Aβ42

Ravit Malishev,† Sukhendu Nandi,‡ Sofiya Kolusheva,‡ Yael Levi-Kalisman,† Frank-Gerrit Klärner,§ Thomas Schrader,§ Gal Bitan,*∥ and Raz Jelinek†

†Department of Chemistry, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
‡Ilse Katz Institute for Nanotechnology, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
§Institute of Organic Chemistry, University of Duisburg-Essen, Essen 45117, Germany
∥Department of Neurology, David Geffen School of Medicine, Brain Research Institute, and Molecular Biology Institute, University of California at Los Angeles, Los Angeles, California 90095, United States

ABSTRACT: Although the precise molecular factors linking amyloid β-protein (Aβ) to Alzheimer’s disease (AD) have not been deciphered, interaction of Aβ with cellular membranes has an important role in the disease. However, most therapeutic strategies targeting Aβ have focused on interfering with Aβ self-assembly rather than with its membrane interactions. Here, we studied the impact of three toxicity inhibitors on membrane interactions of Aβ42, the longer form of Aβ, which is associated most strongly with AD. The inhibitors included the four-residue C-terminal fragment Aβ(39−42), the polyphenol (−)-epigallocatechin-3-gallate (EGCG), and the lysine-specific molecular tweezer, CLR01, all of which previously were shown to disrupt different steps in Aβ42 self-assembly. Biophysical experiments revealed that incubation of Aβ42 with each of the three modulators affected membrane interactions in a distinct manner. Interestingly, EGCG and CLR01 were found to have significant interaction with membranes themselves. However, membrane bilayer disruption was reduced when the compounds were preincubated with Aβ42, suggesting that binding of the assembly modulators to the peptide attenuated their membrane interactions. Importantly, our study reveals that even though the three tested compounds affect Aβ42 assembly differently, membrane interactions were significantly inhibited upon incubation of each compound with Aβ42, suggesting that preventing the interaction of Aβ42 with the membrane contributes substantially to inhibition of its toxicity by each compound. The data suggest that interference with membrane interactions is an important factor for Aβ42 toxicity inhibitors and should be taken into account in potential therapeutic strategies, in addition to disruption or remodeling of amyloid assembly.

KEYWORDS: Molecular tweezer, membrane interactions, amyloid β-protein (Aβ), polyphenol, fibril inhibitors

The transformation of soluble proteins into toxic oligomers and amyloid fibrils is a key pathologic process in devastating medical disorders, including Alzheimer’s disease (AD), Parkinson’s disease, and type-II diabetes.1−3 Though the presence of fibrillar aggregates appears to be a universal phenomenon in amyloid diseases, the relationship between amyloid formation, disease progression, and pathogenicity remains unclear. Amyloid plaques, in which the main component is the amyloid β-protein (Aβ), particularly its longer form, Aβ42, are a pathologic hallmark of AD. Aβ oligomers, which form as intermediates in the plaque-formation process and are considered the proximal neurotoxins in AD, have been reported to cause membrane leakage, either through nonspecific pore formation or via other mechanisms.4−6 A two-step mechanism for Aβ42−membrane interactions has been recently reported.6 Accordingly, understanding the mechanistic aspects of Aβ42 interactions with cellular membranes has been the focus of intensive research.7−10 Diseases associated with protein misfolding and aggregation, including AD, are currently incurable. Therefore, extensive research effort has been directed at developing inhibitors and modulators of protein aggregation and exploring their therapeutic potential. Notably, however, despite strong evidence for involvement of lipid and membrane interactions of misfolded proteins in the cytotoxicity of amyloidogenic proteins,11,12 development of therapeutic drugs targeting protein misfolding and aggregation largely has neglected this aspect of the pathologic mechanism and focused almost exclusively on substances that interfere with the self-assembly processes of amyloid proteins, such as Aβ42.

Numerous molecules have been evaluated for their effect on Aβ self-assembly and toxicity.13−16 Peptide fragments compris-
ing discrete short sequences within Aβ42 have been shown to reduce cytotoxicity in cell culture and in vivo, presumably through binding to Aβ42 at early aggregation stages, thereby inhibiting formation of the toxic oligomers.17,18 Polyphenols, such as resveratrol (found in red grape skin and seeds)19,20 and (−)-epigallocatechin-3-gallate (EGCG, a component of green tea),21,22 have been among the most widely studied inhibitors of cytotoxicity and fibril formation of amyloid proteins. These molecules have attracted much attention because they are nutraceuticals; they exist in different food sources and therefore are considered bioavailable and safe. Another attractive feature is that many of them also have antioxidant and anti-inflammatory activities.23,24 EGCG, in particular, is a broad-spectrum inhibitor, previously shown to interfere in the Aβ42 fibrillation process at different stages, blocking toxic oligomer assembly,22,25,26 and inducing fibril disassembly.27,28 Amyloid inhibitory effects of small compounds derived from natural products have also been recently reported.29

Using a different approach, recent studies have identified a synthetic lysine-binding “molecular tweezer” called CLR01 as a powerful modulator of the self-assembly and a general inhibitor of the toxic effect of amyloid proteins, including Aβ42.30,31 The mechanism of action of CLR01 is reversible binding to exposed lysine residues, which disrupts electrostatic and hydrophobic interactions involving lysines and leads to remodeling of the assembly process into formation of nontoxic and non-amyloidogenic structures that can be effectively degraded by the natural clearance mechanisms. Because the binding is highly labile and occurs with micromolar affinity and because in misfolded proteins lysines tend to be more exposed to the solvent than in typical globular proteins,32 at the concentrations needed for inhibition, CLR01 does not interfere with normal protein structure or function.31,33

Here, we specifically address the participation of membranes in amyloid toxicity inhibition through investigating the effect of three modulators, Aβ(39–42), EGCG, and CLR01, on membrane interactions of Aβ42. These three inhibitors were chosen because they represent a variety of features some of which overlap and some that are unique to each compound (Table 1). Different than most assembly modulation studies

<table>
<thead>
<tr>
<th>Table 1. Details of the Assembly Modulators Studied</th>
</tr>
</thead>
<tbody>
<tr>
<td>compound</td>
</tr>
<tr>
<td>type</td>
</tr>
<tr>
<td>specificity</td>
</tr>
<tr>
<td>binds monomers</td>
</tr>
<tr>
<td>binds oligomers</td>
</tr>
<tr>
<td>specific binding</td>
</tr>
<tr>
<td>region</td>
</tr>
</tbody>
</table>

“Specificity refers to whether the compound binds one particular target or multiple targets, as well as targeting particular assembly states, monomers, oligomers, or fibrils.22,30,31

reported to date, the focus of our study was on the ternary interactions among Aβ42, the assembly modulators, and membrane lipid bilayers. As such, our work illuminates a rarely studied angle of assembly modulators’ activity, their effect on membrane interactions of Aβ. The data reveal that the interactions between Aβ42 and each assembly modulator effectively “shield” the membrane, not only blocking membrane interactions of Aβ42 but also, surprisingly, inhibiting bilayer disruption by the assembly modulators themselves.

## RESULTS AND DISCUSSION

Figure 1 shows the assembly modulators studied here and their putative effects on the Aβ42 assembly process. We selected these modulators because they belong to distinct molecular classes and they remodel Aβ42 using different mechanisms. Specifically, Aβ(39–42) (Figure 1A) comprises the four-residue C-terminal sequence of Aβ42 (Val-Val-Ile-Ala), which was shown to reduce Aβ42 neurotoxicity by remodeling its oligomerization but did not affect Aβ42 fibrillation.18,34–36 EGCG is a polyphenol extracted from green tea known to bind Aβ monomers and oligomers selectively.34,35 CLR01 is a molecular tweezer that binds Aβ monomers and oligomers noncovalently, thereby remodeling Aβ42 assembly and inhibiting its toxicity.30,39,40 CLR01 also can disaggregate preformed Aβ fibrils, albeit with much slower kinetics than EGCG. Both EGCG and CLR01 are broad-spectrum assembly modulators that have been shown to be effective inhibitors of the toxicity of multiple amyloidogenic proteins,38,41 whereas Aβ(39–42) inhibits Aβ42 selectively.34,35

Figure 1B summarizes the putative stages of the Aβ42 assembly process affected by each modulator.34,35,39,42 It should be emphasized, however, that although the inhibition mechanisms depicted in Figure 1B are based on experimental analyses, the effects of the modulators in the presence of membranes and the interplay between assembly modulation and membrane interactions have not been addressed previously.

We compared first the fibrillation kinetics of Aβ42 modulator mixtures in buffer alone and in the presence of DMPC/DMPG vesicles. This vesicle composition has been employed widely as
The assembly modulators had distinct effects on the fibrillation kinetics (Figure 2). The ThT fluorescence curves corresponding to the Aβ42/Aβ(39−42) mixture, both in buffer and in vesicle solutions, were almost identical to those of Aβ42 alone, in agreement with a previous report that Aβ(39−42) did not significantly affect the extent or kinetics of Aβ42 fibril formation.58 In contrast, no increase in ThT fluorescence was observed in the presence of either EGCG or CLR01. In fact, in the presence of EGCG in buffer alone the initial fluorescence was substantially lower than in any of the other cases (Figure 2A). These data are in agreement with a previous report indicating that in addition to preventing Aβ fibril formation, EGCG competes with ThT binding to Aβ,37 presumably leading to the apparent low fluorescence. In the presence of the lipid vesicles, the initial ThT fluorescence of the Aβ42/EGCG mixture was similar to that of the other reactions and then decreased gradually over time (Figure 2B), suggesting that initially the vesicles might shield, at least partially, the binding sites on Aβ from EGCG but not from ThT.

A lack of increase in ThT fluorescence intensity was observed also in the presence of CLR01 (Figure 2), which is not known to affect ThT binding to Aβ. Therefore, these data likely point simply to inhibition of β-sheet formation of Aβ42 by CLR01 regardless of the presence of the vesicles. Overall, the ThT fluorescence data suggest that the three modulators behave similarly in the presence of lipid vesicles to the way they behave in simple buffer solutions; namely, Aβ(39−42) does not affect fibril formation,34 CLR01 prevents Aβ42 fibrillogenesis, whereas conclusions regarding the effect of EGCG on fibrillogenesis cannot be made due to its competition with ThT.39

Cryo-TEM analysis (Figure 3) corroborated the ThT data and provided a visual depiction of the effect of the modulators on Aβ42 in the presence of lipid vesicles. TEM examination of Aβ42 in the presence of each modulator in simple buffers has been reported previously30,34,51 and therefore is not shown.
Here, Aβ42 alone or in the presence of Aβ(39–42) (as well as in the presence of DMPC/DMPG vesicles) formed abundant fibrils (Figure 3A,B), whereas when co-incubated with EGCG or CLR01 only scarce fibrils were observed (Figure 3C,D). Together, the ThT (Figure 2) and microscopy (Figure 3) experiments indicate that the effects of the three assembly modulators on Aβ42 fibrillation in the presence of lipid vesicles are similar to their effects in the absence of membranes.

To gain further insight into the impact of the ternary interactions among Aβ42, lipid vesicles, and assembly modulators on the changes in the secondary structure of Aβ42 during its self-assembly, we used CD spectroscopy (Figure 4). The CD spectra of Aβ42 in buffer alone showed a change from an initial mixture of statistical coil and β-sheet to a predominantly β-sheet conformation, reflected in spectral maxima at 195–198 nm and minima at 217–218 nm (Figure 4A).52 Consistent with previous studies,53 the presence of the lipid vesicles promoted β-sheet formation of Aβ42, giving rise particularly to increased intensity of the maxima at 195–198 nm (Figure 4B).

The three inhibitors had distinct effects on the folding of Aβ42 in the presence of vesicles (Figure 4C–E). Aβ(39–42) appeared not to disrupt β-sheet formation, although signal intensity was reduced by the peptide fragment (Figure 4C). Both EGCG and CLR01, however, significantly disrupted the β-sheet conformation of Aβ42. In the case of EGCG addition, the initial spectrum was nearly flat with a shallow minimum at 209 nm. Upon incubation, a maximum developed at 211 nm and a minimum at 228 nm pointing to irregular coil conformations. The CD spectra observed in the presence of CLR01 suggested traces of β-sheet initially (red spectrum, Figure 4E). By 4 h, a conformational transition took place leading to a shift of the minimum to 210 nm and a decrease in its amplitude, suggesting development of disordered structures.

Overall, the CD spectra indicate that EGCG and CLR01 but not Aβ(39–42) perturbed the structure of Aβ42 during the first hours of the assembly reaction and attenuated formation of the typical cross-β structure of amyloid fibrils. Similar conformational rearrangements were recorded without DMPC/DMPG vesicles present (Supplementary Figure 1).

In the next part of the study, we focused on the effect of Aβ42, the assembly modulators, and their mixtures on the membrane-bilayer structure and properties. First, we examined how addition of Aβ42 in the absence or presence of each modulator might affect membrane structure and dynamics. To address this question, we measured Förster resonance energy transfer (FRET) between a lipid-attached fluorescent donor, N-NBD-PE, and acceptor, N-Rh-PE, embedded in DMPC/DMPG vesicles. FRET has been widely used for investigating bilayer dynamics and effects of membrane-active compounds.54,55 Addition of Aβ42 to the vesicles caused an increase of ∼30% in FRET efficiency for the duration of the experiment (Figure 5). This increase was not due to interaction of Aβ42 with the donor or acceptor themselves, because on their own, both N-NBD-PE and N-Rh-PE displayed a ∼10% decrease in fluorescence in the presence of Aβ42 (data not shown). The increase above the baseline FRET efficiency (e.g., 100%) suggested that some clustering of the fluorescence donor and acceptor molecules might have occurred, leading to more efficient energy transfer.

Figure 5 shows that addition of Aβ(39–42) had a smaller effect, increasing FRET efficiency by ∼10% relative to baseline, suggesting weaker interaction of the tetrapeptide with the
vesicles. The FRET efficiency in the presence of the Aβ42/Aβ(39–42) mixture appeared to reflect the cumulative effect of both peptides, reaching ∼40% increase in efficiency. CLR01 caused a gradual decrease in FRET efficiency to ∼90% over the duration of the experiment (Figure 5). This effect might be ascribed to weak quenching of the fluorescence by CLR01 or to perturbation of the membrane by CLR01. Interestingly, when a mixture of CLR01 and Aβ42 was incubated with the vesicles, the FRET efficiency was ∼10% above baseline, suggesting that the interaction between Aβ42 and CLR01 negated the individual effect of the peptide (∼30% increased FRET) and the molecular tweezer (∼10% decreased FRET) on their own. The data also suggested that the decrease in FRET efficiency in the presence of CLR01 alone was due to membrane perturbation rather than quenching. FRET experiments examining the effect of EGGCG were inconclusive, since EGGCG had a significant quenching effect of both membrane-embedded fluorophores (Supplementary Figure 2).

To gain further insight into the impact of Aβ42 and the modulators on the membrane structure and dynamics, we used giant vesicles decorated with amphiphilic fluorescent carbon dots and examined them by confocal fluorescence microscopy (Figure 6). Carbon dots are bright, multicolored imaging agents that can be coupled readily to biological assemblies such as cells and vesicles, enabling diverse spectroscopic and microscopic visualization capabilities. A recent study demonstrated that amphiphilic carbon dots could be adsorbed onto the lipid bilayers of giant unilamellar vesicles (GUVs) thereby providing a tool for visualization of membrane-associated processes and vesicle dynamics.

The lipid vesicles used for the confocal fluorescence microscopy experiments in Figure 6 were PC/PG GUVs, which are substantially larger than the small unilamellar DMPC/DMPG vesicles employed in all the experiments described above, to enable microscopic visualization. However, the basic lipid types and polarity of the GUVs were maintained similar to those of the DMPC/DMPG vesicles to allow meaningful comparison with the previous experiments.

Using confocal fluorescence microscopy, we visualized for the first time the effect of Aβ42 on the membrane bilayer within minutes after addition of Aβ42 to lipid vesicles. Prior to addition of Aβ42, the vesicles exhibited a spherical morphology and uniform surface distribution of the carbon dots (Figure 6A). Addition of Aβ42 caused a dramatic time- and concentration-dependent modification of the vesicle surface organization. Addition of 5 μM Aβ42 resulted in slight distortion of the spherical vesicle shape after 10 min (the decrease of the fluorescence signal shown in the figure was recorded also in control vesicles without addition of the peptide and likely is related to bleaching of the fluorescent carbon dots over time). Addition of 15 μM Aβ42 modified the vesicle lipid arrangement more strongly giving rise to shape distortion and formation of distinct brighter and darker domains on the vesicle surface. A remarkable fluorescent “spot” was observed upon incubation of the carbon-dot-labeled vesicles with 30-μM Aβ42.

The clustering of the carbon dots into bright domains is consistent with the FRET results reported above. If similar clustering of the FRET donor and acceptor occurred, FRET efficiency would be higher in the equivalent of the bright domains and lower in the darker domains visualized by the carbon dots. The sum of the change would depend on the specific size and organization of the membrane and, as discussed above, gave rise to an overall increase of ∼30% in FRET efficiency in the presence of Aβ42.

The observed reorganization of the carbon dots upon addition of Aβ42 suggested two possible scenarios: (1) the carbon-dot reorganization reflected the changes in lipid organization within the membrane vesicles rather than direct interactions between Aβ42 and the vesicle-attached carbon dots or (2) the clustering of the carbon dots paralleled and colocalized with self-association and aggregation of Aβ42. To distinguish between these two scenarios, we incubated GUVs with carbon dots under the same conditions as in the previous experiment, but this time added Aβ42 fluorescently labeled at the N-terminal amino group by AlexaFluor 488 (Figure 6B). Examination of the images revealed that unlike the carbon dots, Aβ42 did not aggregate during the short period of interaction with the membrane and remained uniformly dispersed in the vesicle. Thus, the data support the first scenario: Aβ42 induces perturbation of the membrane and causes clustering of the carbon dots but does not coassociate with the carbon dots itself.
Addition of each of the modulators to the PC/PG GUVs caused rearrangement of the carbon dots and in the case of EGCG and CLR01 also distortion of the vesicles. Aβ(39–42) alone induced moderate aggregation of the fluorescent carbon dots on the vesicle surface relative to Aβ/42 and did not change the overall spherical morphology of the vesicle. When Aβ/42 and Aβ(39–42) were coadded to the GUVs, similar vesicle surface reorganization was apparent (Figure 6C), suggesting that regardless of its own membrane activity, Aβ(39–42) offered some protection of the vesicles from the perturbation caused by Aβ/42. A fluorescent “spot” was apparent, similar to the one induced by Aβ/42 alone, yet the remaining surface of the vesicle did not become dark to the same extent as with Aβ/42 alone (Figure 6A).

In our study design, Aβ/42 and the modulators were mixed together prior to addition to the vesicles. This strategy was used to ascertain that neither Aβ/42 nor the modulators exhibit (their intrinsic) membrane interactions, and accordingly the analysis would reveal whether new modes of membrane interactions occurred when the peptide and modulators interacted in solution. To validate that the effect of the compounds indeed was on each other, we also tested sequential addition, first Aβ/42 and then each of the modulators or vice versa. In all the cases, the initial effect on the distribution of the carbon dots and vesicle shape persisted and was not affected by addition of the second compound (Aβ/42 or any of the modulators, data not shown).

Similar to Aβ/42 and Aβ(39–42), EGCG on its own also modified the distribution of the fluorescent carbon dot on the vesicle surface (Figure 6C). In addition, EGCG caused some distortion of the spherical morphology of the vesicle. The area in which the carbon dots concentrated appeared to protrude above the vesicle surface. Interestingly, when EGCG and Aβ/42 were coadded to the GUVs, the vesicle morphology and surface appearance were almost identical to the control vesicles (Figure 6C), suggesting that interaction between Aβ/42 and EGCG inhibited membrane disruption and reorganization by both molecules.

CLR01 had the strongest impact on the membrane among the three modulators, inducing pronounced distortion of the spherical vesicle morphology. As observed with EGCG, when CLR01 was co-incubated with Aβ/42, the effect of the molecular tweezer on the vesicles was substantially less pronounced. In the presence of the Aβ/42/CLR01 mixture the vesicles retained their spherical morphology and the clumping of the carbon dots into a bright patch resembled the effect of Aβ/42 by itself (Figure 6C).

Because all three modulators appeared to perturb the lipid vesicles, we asked whether this was due to general nonspecific interactions with the vesicles or the carbon dots. To answer this question, we used two unrelated compounds, the anti-inflammatory sesquiterpene lactone parthenolide and the pentapeptide Asp-Phe-Asn-Met-Phe (a short fragment within the protein hormone calcitonin). Neither compound affected the distribution of the carbon dots under identical conditions (Figures 6D,E, respectively), suggesting that the observed membrane perturbation was not due to nonspecific interactions.

This study examined the relationship between the action of Aβ/42 toxicity inhibitors and membrane interactions. This aspect of the antitoxic activity of compounds with therapeutic potential in amyloid diseases often has been overlooked although membrane interactions likely have important roles in mediating the toxic effects of amyloid proteins. Our data clearly show that for the three molecules examined, each representing a distinct class of antitoxic agents, incubation and association with Aβ/42 substantially modulated membrane interactions.

The data confirmed that lipid vesicles promote β-sheet formation and fibril assembly by Aβ/42. The distinct role of the vesicle environment was particularly apparent in the ThT fluorescence assay, which demonstrated elimination of the lag phase in the presence of vesicles, in contrast to the buffer solution (Figure 2). Similarly, the CD data showed accelerated and enhanced β-sheet formation when Aβ/42 was incubated with DMPC/DMPG vesicles (Figure 4A,B). In the reverse direction, that is, the impact of Aβ/42 on the membrane, FRET analysis showed an increase in FRET efficiency between lipid-embedded donor and acceptor upon addition of Aβ/42 to DMPC/DMPG vesicles (Figure 5A), suggesting that Aβ/42 induced clustering of the donor and acceptor. This interpretation was supported by fluorescence microscopy imaging of PC/PG GUVs labeled with amphiphilic carbon dots. Taken together, the data suggest that Aβ/42 causes a substantial and rapid (within a few minutes) lipid reorganization.

Each of the three assembly modulators examined displayed its known effect in solutions containing buffer alone, confirming previous results. The presence of the lipid vesicles had a relatively minor effect on the activity of the modulators. Thus, EGCG and CLR01 prevented the ThT fluorescence increase by Aβ/42 regardless of the presence of the lipid vesicles, whereas Aβ(39–42) had no effect, similar to the findings in buffer alone (Figure 2). Cryo-TEM examination of Aβ/42 in the presence of vesicles revealed formation of scarce, occasional fibrils in reaction mixtures with EGCG or CLR01 (Figure 3). Similarly, the presence of lipid vesicles induced only minor changes in the CD spectra of Aβ/42 in the presence of each modulator, and the kinetics of secondary-structure transition remained largely the same in each case (Figure 4). Overall, the data supported the notion that Aβ/42 aggregation is facilitated by lipid vesicles but suggested that disruption of the aggregation by effective assembly modulators, such as EGCG or CLR01, is not affected by the membranes. In other words, in the push–pull competition between the membranes and the modulators, the modulators have the upper hand.

In the case of EGCG, this conclusion contradicts the observations by Engel et al., who reported that EGCG was a substantially less efficient inhibitor of amyloid formation by islet amyloid polypeptide (IAPP) in the presence of phospholipids than in simple buffer solutions.57 The difference between our results and those of Engel et al. may simply reflect the fact that Aβ/42 and IAPP are different peptides. In addition, conceivably, the differences could also be related to the distinct charge states of IAPP and Aβ/42. In both studies, the vesicles had a negatively charged surface. We used a mixture of neutral DMPC and negatively charged DMPG, and Engel et al. used negatively charged dipalmitoylphosphatidylglycerol (DPPG) vesicles. In contrast to Aβ/42, which has a net charge of −3 at physiologic pH, IAPP has a net charge of +3, which makes its attraction to the vesicles substantially higher than that of Aβ, providing a plausible explanation for the lower impact of EGCG on IAPP than on Aβ/42 in the presence of negatively charged vesicles. If this explanation is correct, the opposite would be expected in the presence of positively charged lipid membranes, that is, EGCG would be expected to have a lower effect on Aβ/42.
aggregation than on IAPP aggregation. Moreover, different lipid binding mechanisms may also play role. IAPP contains an amphipathic α-helix that can participate in binding membranes; whereas, the Aβ peptide seems to anchor into membranes more directly via the hydrophobic C-terminus.

In contrast to the unremarkable impact of the membrane vesicles on the capability of the modulators to impact Aβ/42 assembly, both Aβ/42 and each modulator appeared to have a substantial impact on the organization and dynamics of the lipid molecules within the vesicles. This was apparent by FRET measurements, which suggested that Aβ/42 and, to a lower extent, Aβ/(39−42) induced rapid clustering of the FRET donor and acceptor. In contrast, CLR01 caused slow reduction of the FRET efficiency reaching a ~10% decrease by 2 h, suggesting perturbation of the vesicles in a manner that increased the average distance between the donor and acceptor molecules.

Interestingly, this effect was reversed when CLR01 was added to the vesicles in the presence of Aβ/42, even though the concentration of CLR01 was 5-times that of Aβ/42.

These observations could be explained by the fact that Aβ/42 may bind up to three CLR01 molecules" and suggest that the affinity of CLR01 for Aβ/42 is substantially higher than that for the vesicles, which would be expected, because the molecular tweezer is known to bind with low micromolar affinity to lysine residues. In addition, CLR01 binds arginine residues with 5−10 times lower affinity. Upon binding of CLR01 to the lysine and arginine residues in Aβ, the charge of these residues is reversed for each lysine or arginine residue from positive (+1) to negative (ca. −2) depending on the protonation state of the CLR01 phosphate groups, increasing the net charge of Aβ/42 from −3 to −6. Thus, the complex of Aβ/42 and CLR01 is expected to have a lower affinity for the membrane vesicles than Aβ/42 alone. Similarly, the tendency of CLR01 to interact with the phospholipid molecules was reduced, likely due to engagement of its hydrophobic “arms” with the peptide, making them less available for interaction with the membrane.

The fluorescence microscopy experiments utilizing carbon-dotted-labeled GUVs revealed that when each of the compounds we used (including Aβ/42 itself) was added individually to the vesicles it induced bilayer reorganization and in some cases caused different degrees of deformation of the globular structure of the vesicle. These membrane interactions were weaker in each case when instead of the individual compound, the mixture of each modulator with Aβ/42 was added to the lipid vesicles, supporting the notion that in the interplay of the interaction of Aβ/42, the lipid vesicles, and the toxicity inhibitors, the binding of the inhibitors to Aβ/42 was the predominant interaction, overshadowing the interaction between Aβ/42 and the membrane or the modulators and the membrane.

The data suggest that the interaction of Aβ/42 with effective assembly modulators, EGCG and CLR01, is stronger than its interaction with membranes and that interaction with all three toxicity inhibitors partially shields Aβ/42 from interacting with the membranes, contributing to the protective effect of these compounds. An open and intriguing question, which will require additional future investigation, is why the interaction of each of the compounds with the lipid vesicles, which in certain cases appeared to induce stronger perturbation than that of Aβ/42, does not lead to apparent toxicity. Further high-resolution structural insights into the inhibitor−peptide−membrane system will contribute to better understanding of these issues.

## METHODS

### Materials

Aβ/42 was purchased from AnaSpec (USA) in a lyophilized form at >95% purity. Aβ(39−42) was purchased from Peptron (South Korea) in a lyophilized form at >90% purity. L-α-Phosphatidylcholine (egg, chicken), L-α-phosphatidylglycerol (egg, chicken, sodium salt), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2,1,3-benzoxadizol-4-yl) (N-NTBD-PE), and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (N-Rh-PE) were purchased from Avanti Polar Lipids. Thioflavin T (ThT), 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), sodium hydroxide, sodium phosphate monobasic, and EGCG, >95% purity, were purchased from Sigma-Aldrich (Rehovot, Israel). CLR01 was prepared and purified as a Li+ salt as described previously.

### Peptide and Sample Preparations

Aβ/42 was dissolved in HFIP at a concentration of 1 mg/mL and stored at −20 °C until use to prevent aggregation. For each experiment, the solution was thawed, and the required amount was dried by evaporation for 6−7 h to remove the HFIP. The dried peptide sample was dissolved in 10 mM sodium phosphate, pH 7.4, at room temperature. Stock solutions of Aβ/(39−42), EGCG, and CLR01 were prepared at 5 mM in deionized water and diluted into the Aβ/42 solutions at the required concentration.

### Thioflavin T (ThT) Fluorescence Assay

ThT fluorescence measurements were conducted at 37 °C using 96-well plate cell culture plates on a Varioskan plate reader (Thermo, Finland). Measurements were made on samples containing 30 μM Aβ/42 in the absence or presence of Aβ(39−42), EGCG, or CLR01 at 1:5 Aβ/42/inhibitor concentration ratio and in the absence or presence of lipid vesicles (final concentration 1 mM). A 192-μL aliquot of the aggregation reaction was mixed with 48 μL of 100 μM ThT in sodium phosphate, pH 7.4, at different time points. The fluorescence intensity was measured following a 10 min incubation at λex = 440 and λem = 485 nm.

### Cryogenic Transmission Electron Microscopy (Cryo-TEM)

Cryo-TEM imaging of aliquots taken from the same reaction mixtures used in the ThT experiments after 12-h incubation was carried out as follows: A 3-μL droplet of the reaction mixture was deposited on a glow-discharged TEM grid (300 mesh Cu Lacey substrate grid; Ted Pella). The excess liquid was blotted with a filter paper, and the specimen was rapidly plunged into liquid ethane precooled with liquid nitrogen in a controlled environment (Leica EM GP). The vitrified samples were transferred to a cryo-specimen holder (Gatan model...
626) and examined at −181 °C using a FEI Tecnai 12 G2 TWIN TEM operated at 120 kV in low-dose mode. Grids were imaged a few micrometers under focus to increase phase contrast. The images were recorded with a Gatan charge-coupled device camera (model 794) and analyzed by Digital Micrograph software, Version 3.1.

**Circular Dichroism (CD) Spectroscopy.** CD spectra were recorded in the range of 190–260 nm at room temperature on a Jasco J-715 spectropolarimeter, using 1 mm quartz cuvettes. Solutions composed of 400 μL contained 50 μM Aβ/42 in the absence or presence of 5-fold excess Aβ/(39–42), EGCG, or CLR01 and in the absence or presence of 1 mM lipid vesicles. Spectra were recorded every 1 h for 4 h. CD signals resulting from vesicles and buffer were subtracted from the corresponding spectra.

** Förster Resonance Energy Transfer (FRET).** Small unilamellar vesicles (SUVs, DMPG/DMPC at 1:1 molar ratio) were prepared by dissolving the lipid components in chloroform/ethanol and drying under vacuum, followed by dissolution in sodium phosphate, pH 7.4, and sonication of the aqueous lipid mixture at room temperature for 10 min using a Sonics vibracell VCX130 ultrasonic cell disrupter. Prior to drying, the lipid vesicles were supplemented with N-NBD-PE and N-Rh–PE at a 500:1:1 molar ratio, respectively. Aβ/42 (30 μM) in the absence or presence of Aβ/(39–42), EGCG, or CLR01 at 1:5 Aβ/42/modulator concentration ratio was added to the vesicles (final vesicle concentration 1 mM) at t = 0. Fluorescence emission spectra were acquired at different time points up to 2 h (λex = 469 nm) in the range of 490–650 nm using a Varioskan 96-well plate reader (Thermo, Finland).

To calculate the extent of FRET efficiency, the following equation was used:

\[
\text{efficiency} = \frac{R_1 - R_{100\%}}{R_0 - R_{100\%}} \times 100\%
\]

in which R is a ratio of fluorescence emission of NBD-PE (531 nm)/rhodamine B-PE (591 nm), \(R_0\) is the ratio in the peptide/vesicle mixtures, \(R_{100\%}\) was measured following the addition of 20% Triton X-100 to the vesicles, which causes complete dissolution of the vesicles, and \(R_1\) corresponds to the ratio recorded for vesicles without any additives.

**Giant Unilamellar Vesicles Labeled with Amphiphilic Carbon Dots.** Amphiphilic carbon dots were prepared according to a published protocol. Briefly, preparation of the carbon dots was carried out in an aqueous solution, and started with O.O’-dilauroyl tartaric acid anhydride produced through reacting t-tartaric acid with laurel chloride. Subsequent reaction with 9-glucose and hydrothermal carbonization yielded carbon dots exhibiting inner graphitic cores coated with an amphiphilic layer comprising alkyl chains and carboxylic acid moieties.

**Confocal Fluorescence Microscopy.** GUVs were imaged in the absence or presence of Aβ/42, inhibitors, or their mixtures using a PerkinElmer UltraVIEW system equipped with an Axiovert-200 M (Zeiss, Germany) microscope and a Plan-NeoFluar 63X/1.4 oil objective. The excitation wavelengths of 440 and 488 nm were generated by an Ar/Kr laser.

**REFERENCES**


Permeabilization are Distinct Processes Influenced Separately by Membrane Charge and Fluidity. J. Mol. Biol. 386, 81–96.


